Clinical trials: Liver Cirrhosis, Alcoholic
Endothelial Dysfunction, Nutritional Status
Effect of Non-alcoholic Beer in Cirrhosis
The implementation of nutritional strategies targeting several variables at once could benefit patients with cirrhosis. Non-alcoholic beer has different compounds derived from hops that exert antioxidant, anti-inflammatory and…
- Conditions
- Endothelial Dysfunction, Nutritional Status, Quality of Life
- Trial name
- LFN-NAB (NCT04041115)
- Testing
- Non-alcoholic beer, control
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Alcoholic Liver Disease, Alcoholic Fibrosis of Liver
Early Detection of Alcoholic Liver Disease
This is an observational study to identify the prevalence of advanced liver fibrosis among patients with excessive alcohol intake using a non-invasive method (FibroScan®) and to characterize the main environmental, genetic and…
- Conditions
- Alcoholic Liver Disease, Alcoholic Fibrosis of Liver, Alcoholic Cirrhosis, Excessive Drinking
- Trial name
- NCT04070508
- Sponsor
- University of Pittsburgh
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
Non-alcoholic fatty liver disease is a major health problem worldwide. It includes simple steatosis and NASH which has inflammation in the liver, with or without fibrosis.
- Trial name
- NCT05384652
- Where
- Hong Kong
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
NAFLD, Alcohol-Related Disorder
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study)
The main objective is to determine the performance of the simple eLIFT blood test for advanced liver fibrosis screening in NAFLD and/or alcoholic patients in primary care.
- Conditions
- NAFLD, Alcohol-Related Disorder, Liver Fibrosis
- Trial name
- IMPROVE (NCT04146636)
- Testing
- e-LIFT
- Where
- France
- Volunteers
- 282 people
- Sponsor
- University Hospital, Angers
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study is open to adults who are at least 18 years old living with obesity and have: a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and moderate or advanced…
- Trial name
- NCT06632444
- Testing
- Survodutide
- Where
- 532 sites in United States, Argentina and 35 more
- Volunteers
- 1,800 people
- Sponsor
- Boehringer Ingelheim
Liver Cirrhosis, Alcoholic
SMS-based Lifestyle Intervention for Patients With Liver Cirrhosis With Previous Hepathic Encephalopathy
To investigate whether simple reminders about healthy lifestyle sent via mobile phone text messages can improve the liver cirrhosis severity and prognosis (as assessed by the MELD score supported by the Child-Pugh score) among…
- Trial name
- SMILE (NCT02811887)
- Testing
- Supervised exercise, Usual Care, SMS-messages
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Marius Henriksen
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Non-alcoholic Steatohepatitis (NASH)
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Trial name
- TANDEM (NCT03517540)
- Testing
- Tropifexor (LJN452), Cenicriviroc (CVC)
- Where
- 65 sites in United States, Argentina and 15 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Non-alcoholic Steatohepatitis (NASH)
Endoscopic Bariatric Therapy in NASH Cirrhosis
Non-alcoholic steatohepatitis (NASH) is a growing public health problem that affects more than 5% of the population and can lead to cirrhosis and hepatocellular carcinoma.
- Trial name
- ETHIC (NCT04281303)
- Testing
- Endoscopic vertical gastroplasty
- Volunteers
- 10 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Alcoholic Hepatitis
Pegfilgrastim in Patients With Alcoholic Hepatitis
This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.
- Trial name
- NCT02776059
- Testing
- Standard of care + pegfiltrastim, Standard of care
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Timothy Morgan, MD
Obesity, NAFLD
Bariatric Endoscopy and NAFLD
Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver disease.
- Conditions
- Obesity, NAFLD, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT04669470
- Testing
- bariatric endoscopy, mainly intragastric baloons, plication of stomach too
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University of Ostrava
NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
The investigators use machine learning capabilities on massive electronic health records for the purpose of developing a model that prioritizes individuals at high risk of progressing to liver cirrhosis, and validating it with…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT05218538
- Testing
- Fibroscan (non interventional)
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- HaEmek Medical Center, Israel
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Study in Healthy Adults Evaluating PF-07202954
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
- Trial name
- NCT04857437
- Testing
- PF-07202954 Repeat Dose, PF-07202954 Single Dose
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Non-Alcoholic Fatty Liver Disease
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.
Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide.
- Trial name
- NAFLD-CARE (NCT04435054)
- Testing
- Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Hospices Civils de Lyon
NAFLD, Liver Cirrhosis
Risk Factors for Advanced Fibrosis Among FLD Patients
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication.
- Conditions
- NAFLD, Liver Cirrhosis, Diabetes Mellitus, Type 2
- Trial name
- FLD_FU_HUS (NCT05971082)
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Decompensated Cirrhosis
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new…
- Trial name
- ENCORE-LF (NCT03205345)
- Testing
- Emricasan (25 mg), Emricasan (5 mg)
- Where
- 76 sites in United States
- Volunteers
- 210 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Non-alcholic Fatty Liver Disease
Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis
Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK) activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1 (S6K1) inhibition.
- Trial name
- NCT02068339
- Testing
- Oltipraz 1 (90mg), Oltipraz 2 (120mg)
- Where
- 5 sites in South Korea
- Volunteers
- 283 people
- Sponsor
- PharmaKing